Zobrazeno 1 - 10
of 43 526
pro vyhledávání: '"Dosage Forms"'
Autor:
Wojtyłko M; Chair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, Poznań, Poland.; School of Pharmacy, Queen's University Belfast, Belfast, UK., Lamprou DA; School of Pharmacy, Queen's University Belfast, Belfast, UK., Froelich A; Chair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, Poznań, Poland., Kuczko W; Institute of Materials Technology, Faculty of Mechanical Engineering, Poznan University of Technology, Poznan, Poland., Wichniarek R; Institute of Materials Technology, Faculty of Mechanical Engineering, Poznan University of Technology, Poznan, Poland., Osmałek T; Chair and Department of Pharmaceutical Technology, Poznan University of Medical Sciences, Poznań, Poland.
Publikováno v:
Expert opinion on drug delivery [Expert Opin Drug Deliv] 2024 Nov; Vol. 21 (11), pp. 1523-1541. Date of Electronic Publication: 2023 Dec 11.
Autor:
Poudel I; Department of Drug Discovery and Development, Auburn University, Auburn, AL, USA., Mita N; Department of Drug Discovery and Development, Auburn University, Auburn, AL, USA.; Faculty of Pharmacy, Mulawarman University, Samarinda, Kalimantan Timur, Indonesia., Babu RJ; Department of Drug Discovery and Development, Auburn University, Auburn, AL, USA.
Publikováno v:
Expert opinion on drug delivery [Expert Opin Drug Deliv] 2024 Nov; Vol. 21 (11), pp. 1595-1614. Date of Electronic Publication: 2024 Jul 24.
Autor:
Salunke S; European Paediatric Formulation Initiative (EUPFI), University College London School of Pharmacy, London WC1N 1AX, UK. Electronic address: s.salunke@ucl.ac.uk., Agrawal A; Novo Nordisk Inc., 300 North Beacon Street, Suite 501, Watertown, MA 02472, USA. Electronic address: vagr@novonordisk.com., Walsh J; Jenny Walsh Consulting, Nottingham, UK. Electronic address: jenny@jennywalshconsulting.com., Nunn A; University of Liverpool, Department of Women's and Children's Health, Liverpool Women's NHS Foundation Trust, Crown Street, Liverpool L8 7SS, UK. Electronic address: tnunn100@hotmail.com., Hughes K; IPEC (International Pharmaceutical Excipients Council) and Colorcon Ltd, Dartford, UK. Electronic address: KHughes@colorcon.com., Kuehl P; F. Hoffmann La Roche AG, Grenzacher Str. 124, CH-4070 Basel, Switzerland., Caivano G; Chiesi Farmaceutici S.p.A., Largo Francesco Belloli 11/A, 43122 Parma, Italy. Electronic address: g.caivano@chiesi.com., Clapham D; Independent Pharmaceutical Consultant, Bishops Stortford, UK. Electronic address: david.clapham@ntlworld.com., Thompson K; Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA. Electronic address: karen_thompson@merck.com., Rumondor A; Bristol Myers Squibb, One Squibb Drive, New Brunswick, NJ 08901, USA. Electronic address: Alfred.Rumondor@bms.com., Enright B; Abbvie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USA. Electronic address: Brian.Enright@abbvie.com., Sherratt P; Bristol Myers Squibb, 556 Morris Avenue, Summit, NJ 07901, USA. Electronic address: Philip.Sherratt@bms.com.
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2024 Oct; Vol. 203, pp. 114458. Date of Electronic Publication: 2024 Aug 17.
Autor:
Agrawal A; Novo Nordisk Inc., 300 North Beacon Street, Suite 501, Watertown, MA 02472, USA. Electronic address: vagr@novonordisk.com., Salunke S; European Paediatric Formulation Initiative (EUPFI), University College London School of Pharmacy, London WC1N 1AX, UK. Electronic address: s.salunke@ucl.ac.uk., Rumondor A; Bristol Myers Squibb, One Squibb Drive, New Brunswick, NJ 08901, USA. Electronic address: Alfred.Rumondor@bms.com., Thompson K; Merck & Co., Inc., 126 E Lincoln Ave, Rahway, NJ 07065, USA. Electronic address: karen_thompson@merck.com., Caivano G; Chiesi Farmaceutici S.p.A. Largo Francesco Belloli 11/A-43122 Parma, Italy. Electronic address: g.caivano@chiesi.com., Walsh J; Jenny Walsh Consulting Ltd., Nottingham, UK. Electronic address: jenny@jennywalshconsulting.com., Enright B; Abbvie Inc. 1 N Waukegan Road, North Chicago, IL, 60064, USA. Electronic address: Brian.Enright@abbvie.com., Sherratt P; Bristol Myers Squibb, 556 Morris Avenue, Summit, NJ 07901, USA. Electronic address: Philip.Sherratt@bms.com., Hughes K; IPEC Europe (International Pharmaceutical Excipients Council) and Colorcon Ltd, Dartford, UK. Electronic address: KHughes@colorcon.com., Clapham D; Independent Pharmaceutical Consultant, Bishops Stortford, UK. Electronic address: david.clapham@ntlworld.com., Kuehl P; F. Hoffmann La Roche AG, Grenzacher Str. 124, CH-4070 Basel, Switzerland. Electronic address: peter.kuehl@roche.com.
Publikováno v:
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V [Eur J Pharm Biopharm] 2024 Oct; Vol. 203, pp. 114447. Date of Electronic Publication: 2024 Aug 08.
Autor:
Paccione N; TECNALIA, Basque Research and Technology Alliance (BRTA), Leonardo Da Vinci 11, 01510 Miñano, Spain; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain, Guarnizo-Herrero V; Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá de Henares, Ctra Madrid-Barcelona Km 33, 600 28805 Madrid, Spain, Ramalingam M; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain; Bioaraba Health Research Institute, Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain.; IKERBASQUE, Basque Foundation for Science, 48013 Bilbao, Spain; School of Basic Medical Sciences, Binzhou Medical University, Yantai 264003, People's Republic of China, Larrarte E; TECNALIA, Basque Research and Technology Alliance (BRTA), Leonardo Da Vinci 11, 01510 Miñano, Spain; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain, Pedraz JL; Joint Research Laboratory (JRL) on Advanced Pharma Development, A Joint Venture of TECNALIA and University of the Basque Country, Centro de investigación Lascaray ikergunea, 01006 Vitoria-Gasteiz, Spain; NanoBioCel Group, Department of Pharmacy and Food Science, Faculty of Pharmacy, University of the Basque Country (UPV/ EHU), 01006 Vitoria-Gasteiz, Spain; Bioaraba Health Research Institute, Jose Atxotegi, s/n, 01009 Vitoria-Gasteiz, Spain; Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Institute of Health Carlos III, 28029 Madrid, Spain.
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society [J Control Release] 2024 Sep; Vol. 373, pp. 463-480. Date of Electronic Publication: 2024 Jul 25.
Designs of clinical swallowability assessments of solid oral dosage forms in regulatory submissions.
Autor:
McGuire MR; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Mostofa A; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Shon J; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Frost M; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Kim MJ; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Li K; Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. Electronic address: karen.li@fda.hhs.gov.
Publikováno v:
International journal of pharmaceutics [Int J Pharm] 2024 Jun 25; Vol. 659, pp. 124229. Date of Electronic Publication: 2024 May 16.
Autor:
Whitaker MCA; Glan Clwyd Hospital, Rhyl, Denbighshire, UK., Whitaker DK; Manchester, UK.
Publikováno v:
Anaesthesia [Anaesthesia] 2024 Jan; Vol. 79 (1), pp. 98-99. Date of Electronic Publication: 2023 Nov 06.
Autor:
Wan M; Evelina Pharmacy, Guys' & St Thomas' NHS Foundation Trust, London, UK mandy.wan@gstt.nhs.uk.; Institute of Pharmaceutical Science, King's College London, London, UK., Wignell A; Pharmacy, Nottingham University Hospitals NHS Trust, Nottingham, UK., Tomlin S; Pharmacy, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Publikováno v:
Archives of disease in childhood [Arch Dis Child] 2023 Dec 14; Vol. 109 (1), pp. 75. Date of Electronic Publication: 2023 Dec 14.
Autor:
Radwan, Aya Saad1 (AUTHOR), Salim, Mohamed M.1,2 (AUTHOR), Belal, Fathalla2 (AUTHOR), Magdy, Galal3,4 (AUTHOR) galal_magdy@pharm.kfs.edu.eg
Publikováno v:
Scientific Reports. 11/11/2024, Vol. 14 Issue 1, p1-11. 11p.
Autor:
Rychlíčková, Jitka1,2 rychlickova@med.muni.cz, Součková, Lenka1,2
Publikováno v:
Klinická Farmakologie a Farmacie. Nov2024, Vol. 38 Issue 3, p112-117. 6p.